---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005911"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:38:50.254511+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics reports record Q4 revenue $5.1M, net loss improves 25% for FY 2024

## Summary
- Q4 2024 revenue $5.1M, up 5% YoY; gross margin 53%, up 400 bps vs 49% in Q4 2023.
- FY 2024 revenue $17.9M, down 2% YoY; net loss $11.3M ($0.56/sh), 25% better than FY 2023.
- Cash and restricted cash $6.5M at Dec 31, 2024; operating cash burn improved to $9.8M from $12.1M.
- Post-year-end, named National Seating & Mobility exclusive U.S. distributor for Ekso Indego Personal device.

## SEC filing metadata
- accession: 0001437749-25-005911
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774925005911/0001437749-25-005911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774925005911/ekso20241114_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005911
- JSON: https://secwatch.observer/filing/0001437749-25-005911.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.